← All indications
Nervous System Neoplasms
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
Subtype terms (5)
More specific conditions that are subtypes of Nervous System Neoplasms in the MeSH hierarchy.
- Central Nervous System Neoplasms
84 drugs (58 approved, 26 experimental)
- Cranial Nerve Neoplasms
- Neurolymphomatosis
- Paraneoplastic Syndromes, Nervous System
- Peripheral Nervous System Neoplasms
1 drug approved
Drugs by status
Phase 3 trials (1)
Phase 2 trials (1)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 3 Indications (59)
- Merck
- Pfizer
- Sugen
- Blaze Bioscience Inc.
- Colorado Health Foundation
- The Christie NHS Foundation Trust
- Medical Research Council
- National Cancer Institute (NCI)
- Maastricht University
- Canadian Cancer Trials Group
- Case Western Reserve University
- Cancer Research Campaign
- Centre Leon Berard
- Children's Cancer and Leukaemia Group
- University of London
- Eastern Cooperative Oncology Group
- Florida International University
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
- Katholieke Universiteit Leuven
- McGill University
- NRG Oncology
- New York University
- North Central Cancer Treatment Group
- Radiation Therapy Oncology Group
- Southwest Oncology Group
- University of Heidelberg
- University of Lausanne
- University of Leicester
- University of Liverpool
- University of Nottingham
- +29 more
Organization Involved with Phase 2 Indications (95)
- Regeneron
- Celgene
- Cephalon
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Roche
- Schering-Plough
- Agouron
- Sanofi
- Novartis
- Bayer
- BeOne Medicines
- CTI BioPharma
- Cortice Biosciences, Inc.
- Direct Therapeutics
- Millennix
- Neurocrine Biosciences
- Avid Bioservices
- Agenus Inc.
- National Institutes of Health (NIH)
- British Columbia Cancer Agency
- National Cancer Institute, France
- Rongjie Tao
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Atlantic Health System
- Baylor University
- Cornell University
- Harvard University
- +65 more
Organization Involved with Phase 1 Indications (32)
- AbbVie
- Daiichi Sankyo
- Pharmacyclics
- Wyeth
- Cavion LLC
- Oncoceutics, Inc.
- PTC Therapeutics
- Vion Pharmaceuticals
- immatics Biotechnologies GmbH
- EpicentRx, Inc.
- Xenova Biomedix
- Cancer Research UK
- University of Washington
- Indiana University
- Medical College of Wisconsin
- Tata Memorial Hospital
- Tufts University
- University of Manchester
- University of Miami
- West Virginia University
- University of Vermont
- University of Colorado, Denver
- Pacira Pharmaceuticals
- Cancer Immunotherapy Trials Network
- University of Mannheim
- Institut de Cancerologie de l'Ouest Paul Papin
- Rush University
- University of Duisburg-Essen
- University of North Carolina at Chapel Hill
- State University of New York, Buffalo
- +2 more
Organization Involved with Other Experimental Indications (8)